

# WOMEN LIVING WITH HIV

While HIV affects everyone differently, women often face particular challenges. Understanding the relationship of being a woman living with HIV and your current HIV treatment regimen may have implications on your decisions now and in the future.<sup>1,2</sup>

THESE ARE A FEW QUESTIONS YOU CAN ASK AT YOUR NEXT VISIT TO HELP YOU AND YOUR DOCTOR MAKE A SUITABLE DECISION FOR YOU.



## LIVING WITH HIV AS A WOMAN

- How does HIV affect my reproductive health?
- What birth control options are available for HIV+ women? Does birth control interact with my HIV medications?
- Does my HIV treatment affect my menstruation?
- How can I protect my partner from the risk of HIV transmission?

## HIV AND PREGNANCY/BREASTFEEDING

- Does being pregnant make my HIV worse?

- What is the risk of HIV transmission to my baby during labour?
- Is my current treatment the best option for women who wish to become pregnant?
- Should HIV medicines be continued during pregnancy and/or breastfeeding?
- Can I breastfeed my baby?


## HIV AND MENOPAUSE

- Does HIV or HIV treatment affect menopause?
- Are there any considerations during menopause for women living with HIV?

## TICK OFF THE QUESTIONS THAT ARE IMPORTANT TO YOU

### ASK YOUR DOCTOR IF DOVATO IS RIGHT FOR YOU

Scan the QR code to learn more and access useful resources available on [WWW.DOVATO.CO.NZ](http://WWW.DOVATO.CO.NZ)



**DOVATO is a prescription only medicine – please consult with your doctor or pharmacist before taking DOVATO.** Side effects people may experience are headache, nausea, and diarrhoea.<sup>3</sup>

**Abbreviations:** HIV, human immunodeficiency virus.

**References:** **1.** HIV.gov. HIV Basics, HIV and women's health issues. Updated April 12th, 2023. Available from: [www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/womens-health-issues/](http://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/womens-health-issues/) (accessed Jan 2024). **2.** Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV, March 2023 (accessed Nov 2023). **3.** GlaxoSmithKline NZ, DOVATO Consumer Medicine Information. 2023. Available at: <https://www.medsafe.govt.nz/consumers/cmi/d/dovato.pdf> (accessed Jan 2024).

**DOVATO** (dolutegravir and lamivudine) is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. **DOVATO is a Prescription Medicine. Dovato has risks and benefits and should be initiated by a doctor experienced in the management of HIV infection. Ask your doctor if DOVATO is right for you. Use strictly as directed.** If you have concerns or if you have side effects, see your doctor, pharmacist, or healthcare professional. Normal doctor's consultation fees apply. For more information, you can view the Dovato Consumer Medicine Information at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Dovato is a funded medicine. Special Authority criteria apply. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. © 2024 ViiV Healthcare group of companies or its licensor. Marketed on behalf of ViiV Healthcare by GlaxoSmithKline NZ Limited, Auckland. **Adverse Events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. Any information provided on this document should be discussed with a healthcare professional and does not replace a healthcare professional's advice.** Date of approval: March 2024 | Date of expiry: March 2026 | TAPS-NP20683 | PM-NZ-DLL-LBND-230003

**This material is intended for NZ audiences only. Any information provided on this document should be discussed with a healthcare professional and does not replace a healthcare professional's advice.**